Suven Life Sciences surges on securing three new product patents

05 Jan 2016 Evaluate

Suven Life Sciences is currently trading at Rs. 267.40, up by 6.90 points or 2.65% from its previous closing of Rs. 260.50 on the BSE.

The scrip opened at Rs. 261.05 and has touched a high and low of Rs. 269.40 and Rs. 258.30 respectively. So far 65192 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 1 has touched a 52 week high of Rs. 338.50 on 15-Apr-2015 and a 52 week low of Rs. 192.15 on 08-Sep-2015.

Last one week high and low of the scrip stood at Rs. 275.20 and Rs. 259.20 respectively. The current market cap of the company is Rs. 3325.25 crore.

The promoters holding in the company stood at 59.57 % while Institutions and Non-Institutions held 7.20 % and 33.23 % respectively.

Suven Life Sciences has secured three product patents; one product patent from Canada, one product patent from ARIPO (AP 3307) and one product patent from South Korea corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with Neurodegenerative diseases and these Patents are valid through 2030.

The granted claims of the patents include the class of selective 5-HT compounds discovered by Suven and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, Attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Parkinson and Schizophrenia.

With these new patents, the company has a total of 21 granted patents from Canada, 2 granted product patents from ARIPO and 19 granted patents from South Korea. These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts. Products out of these inventions may be out-licensed at various phases of clinical development like at Phase-I or Phase-II.

Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies through the use of GPCR targets.

Suven Life Sciences Share Price

170.15 -1.25 (-0.73%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×